Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma

Table 3

Performance of the established radiomics signature in prediction of CK19 status.

	AUC (95% CI)	Threshold	Accuracy	Sensitivity	Specificity	PPV	NPV
AP radiomics signature	0.70 (0.56-0.83)	0.32	0.88	0.37	0.99	0.88	0.88
PVP radiomics signature	0.83 (0.73-0.92)	0.14	0.65	0.89	0.60	0.32	0.96
HBP radiomics signature	0.89 (0.82-0.96)	0.22	0.83	0.79	0.84	0.50	0.95
Fusion radiomics signature^#	0.92 (0.86-0.98)	0.19	0.88	0.84	0.89	0.62	0.96
	0.92 (0.83-0.97)	0.17	0.88	0.84	0.89	0.62	0.96

AFP: alpha fetoprotein; AP: arterial phase; AUC: area under the receiver operating characteristic curve; CI: confidence interval; HBP: hepatobiliary phase; NPV: negative predictive value; PPV: positive predictive value; PVP: portal venous phase. ^#Radiomics model consists of three radiomics scores derived from AP-, PVP-, and HBP-based model.